[{"id":"dec0e27d-576f-4620-b2f7-4fb083164458","acronym":"JAB-21822-1006","url":"https://clinicaltrials.gov/study/NCT05288205","created_at":"2022-03-21T20:54:45.507Z","updated_at":"2025-02-25T16:17:27.931Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","source_id_and_acronym":"NCT05288205 - JAB-21822-1006","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib) • sitneprotafib (JAB-3312)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2022-06-30"}]